Stockscreener 앱 받기
0.6422
0.02%
-0.0079
전일 마감가:
$0.6501
열려 있는:
$0.66
하루 거래량:
39,532
Relative Volume:
0.21
시가총액:
$23.71M
수익:
$98,000
순이익/손실:
$-122.42M
주가수익비율:
-0.1178
EPS:
-5.45
순현금흐름:
$-45.88M
1주 성능:
+0.03%
1개월 성능:
-1.32%
6개월 성능:
-41.96%
1년 성능:
-71.24%
1일 변동 폭
$0.6401
$0.6603
1주일 범위:
$0.636
$0.68
52주 변동 폭
$0.475
$2.7129
Biora Therapeutics Inc Stock (BIOR) Company Profile
명칭
Biora Therapeutics Inc
전화
855-293-2639
주소
4330 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Biora Therapeutics Inc 주식(BIOR)의 최신 뉴스
Biora Therapeutics secures additional $4 million financing - Investing.com
Biora Therapeutics Achieves ISO 13485 Certification - GlobeNewswire
Biora Therapeutics Achieves ISO 13485 Certification - StockTitan
A History of Outperforming Analyst Forecasts and Beating the Odds: Biora Therapeutics Inc (BIOR) - SETE News
Biora Therapeutics Announces Positive Nasdaq Listing Decision - GlobeNewswire
Biora Therapeutics Announces Positive Nasdaq Listing Decision - StockTitan
Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - The Bakersfield Californian
Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Biora Therapeutics secures new financial agreements - Investing.com India
Biora Therapeutics secures new financial agreements - Investing.com
BIOR: Second Quarter Results - Yahoo Finance
Biora Therapeutics, Inc. (NASDAQ:BIOR) Forecasted to Post Q3 2024 Earnings of ($0.42) Per Share - Defense World
BIOR’s Stock Woes: Down -20.37% in 6 Months, Down -20.37% in Just 5 Days - The InvestChronicle
Biora Therapeutics Second Quarter 2024 Earnings: EPS: US$0.18 (vs US$1.47 loss in 2Q 2023) - Yahoo Finance
Biora Therapeutics (NASDAQ:BIOR) Receives “Buy” Rating from HC Wainwright - Defense World
Biora Therapeutics, Inc. (NASDAQ:BIOR) Q2 2024 Earnings Call Transcript - Insider Monkey
Biora Therapeutics maintains stock target after strong Q2 results By Investing.com - Investing.com UK
Earnings call: Biora Therapeutics reports progress on BT-600 and BioJet platforms - Investing.com
Biora Therapeutics Inc (BIOR) Q2 2024 Earnings Call Transcript H - GuruFocus.com
BIOR Stock Earnings: Biora Therapeutics Beats EPS for Q2 2024 - MSN
BIOR Stock Earnings: Biora Therapeutics Beats EPS for Q2 2024 - InvestorPlace
Biora Therapeutics, Inc. (BIOR) Q2 2024 Earnings Call Transcript - Seeking Alpha
Biora Therapeutics Restructures Debt and Issues New Securities - TipRanks
Biora Therapeutics Announces Funding Agreement with Existing Investors - GlobeNewswire
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results - GlobeNewswire
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results - StockTitan
Biora Therapeutics Announces Funding Agreement with Existing Investors - StockTitan
Biora Therapeutics (BIOR) Set to Announce Quarterly Earnings on Monday - Defense World
Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update - GlobeNewswire
Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update - Yahoo Finance
Biora Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference - GlobeNewswire
Biora Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference - StockTitan
HC Wainwright Reiterates Buy Rating for Biora Therapeutics (NASDAQ:BIOR) - Defense World
Biora reports promising BT-600 ulcerative colitis trial results - Investing.com
Anchoring Your Portfolio: Is BIOR Stock a Safe Harbor? - The InvestChronicle
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event - GlobeNewswire
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as ... - The Bakersfield Californian
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event - StockTitan
Biora Therapeutics (NASDAQ:BIOR) Stock Price Up 2.3% - Defense World
Biora Therapeutics Announces Positive Clinical Trial Results for BT-600 - Technology Networks
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ - GlobeNewswire
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024 - Yahoo Finance
BIOR: BT-600 Topline - Yahoo Finance
Market Insights: Biora Therapeutics Inc (BIOR)’s Notable Gain of 3.25, Closing at 0.63 - The Dwinnex
A year in review: Biora Therapeutics Inc (BIOR)’s performance in the last year - US Post News
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Quantisnow
BIORBiora Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Biora Therapeutics Reports Promising BT-600 Trial Results - TipRanks
Biora Therapeutics Announces Positive Clinical Trial Results for BT-600 - GlobeNewswire
Biora Therapeutics To Present On The BioJet Systemic Oral Delivery Platform At The Next Gen Peptide Formulation ... - Quantisnow
Biora Therapeutics Inc (BIOR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.26%
1.71%
자본화:
|
볼륨(24시간):